Drug Information

Drug (ID: DG01710) and It's Reported Resistant Information

Name	Temozolomide/Vandetanib
Synonyms	Temozolomide/Vandetanib Click to Show/Hide
Target	.	NOUNIPROTAC	[1]

Type(s) of Resistant Mechanism of This Drug

UAPP: Unusual Activation of Pro-survival Pathway

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Click to Show/Hide the Resistance Disease of This Class

Brain cancer [ICD-11: 2A00]

Click to Show/Hide

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms
Unusual Activation of Pro-survival Pathway (UAPP)		Click to Show/Hide
Key Molecule: Oxalosuccinate decarboxylase (IDH1)			[1]
Molecule Alteration	Missense mutation	p.R132H (c.395G>A)	Molecule Info
Sensitive Disease	FGFR-tacc positive glioblastoma [ICD-11: 2A00.01]		Disease Info
Experimental Note	Identified from the Human Clinical Data
In Vitro Model	Brain		N.A.
Experiment for Molecule Alteration	Multiplex array; Standard ELISA assay
Experiment for Drug Resistance	Pharmacokinetics analysis

References

Ref 1	A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma PatientsClin Cancer Res. 2015 Aug 15;21(16):3610-8. doi: 10.1158/1078-0432.CCR-14-3220. Epub 2015 Apr 24.

If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.